Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Drug Type, Distribution Channel, Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles. The disease is progressive in nature, meaning it gets worse over time. According to a study published in Centers for Disease Control and Prevention, in 2016, around 14,713 people were diagnosed with ALS in the U.S. and prevalence rate of ALS was 4.7 cases per 100,000 people in 2012. The prevalence rate increased to 5.0 cases per 100,000 people and around 15,908 people were diagnosed with ALS in 2013, according to the same study. The increasing prevalence of ALS is in turn, expected to support growth of the amyotrophic lateral sclerosis (ALS) treatment market in the near future. Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1206 Approval of novel innovative drugs is expected to boost growth in amyotrophic lateral sclerosis treatment market In May 2017, The U.S. Food and Drug Administration (FDA) approved Radicava (edaravone), an innovative drug used in the treatment of amyotrophic lateral sclerosis (ALS). This was the first drug to be approved after over 20 years since the last FDAapproved drug for ALS. The approval of this drug would provide an additional option for patients suffering from this deadly disease. Increasing incidence of ALS is expected to increase the adoption rate of this drug, in turn, boosting market growth. The drug has already been approved in Japan and South Korea in 2015. Report includes chapters which deeply display the following deliverable about industry : • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Research Objective and Assumption • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Regions • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion North America is expected to hold a dominant position in the market, increasing focus of manufacturers on novel drug development for ALS North America is expected to hold a dominant position in the amyotrophic lateral sclerosis treatment market, as major companies present in the region are focusing on collaborations for product development. For instance, in January 2018 Sangamo Therapeutics, Inc. and Pfizer Inc. collaborated for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) for the treatment of ALS. Companies based in emerging economies of Asia Pacific are focusing on developing novel drugs for treatment of ALS. For instant major companies such as Mitsubishi Tanabe Pharma Corporation and Takeda Pharmaceutical Company Ltd are developing drugs for treatment of ALS. Major players operating in the global amyotrophic lateral sclerosis treatment market include Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Ltd., Sanofi S.A., and Mylan Pharmaceuticals Inc. Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/amyotrophic-lateral-sclerosis-treatmentmarket-1206 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Taxonomy The global amyotrophic lateral sclerosis treatment market is segmented on the basis of drug type and distribution channel. On the basis of drug type, the global amyotrophic lateral sclerosis treatment market is segmented into: • Riluzole • Edaravone (Radicava) On the basis of distribution channel, the global amyotrophic lateral sclerosis treatment market is segmented into: • Hospital Pharmacies • Retail & Online Pharmacies About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles.
© Copyright 2024 Paperzz
